Side A · Liner notes
STAT+: Five biotech updates to read after ESMO this weekend
Nutrition · Words by Meghana Keshavan · Released
Moderna and Merck are racing to submit their personalized cancer vaccine for FDA approval, expected in 2027, according to Moderna CEO Stéphane Bancel.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Soundtrack at present: Iggy Pop, The Idiot.
Moderna CEO sees vaccine possibility beyond melanoma
Moderna CEO Stéphane Bancel is looking well beyond melanoma after the company’s personalized cancer vaccine, intismeran, succeeded in a pivotal Phase 3 trial. In an interview with STAT at the ESMO meeting in Madrid, Bancel said Moderna and partner Merck are racing to submit the vaccine for FDA approval, which he expects in 2027. The companies, he said, are also preparing to test it aggressively in other cancers.
